Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun An
investigational inhibitor of theprotein mTOR (mammalian target of rapamycin).
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word ridaforolimus.
Examples
-
Inc. said they have restructured their collaboration related to the treatment ridaforolimus, which is currently being evaluated for multiple types of cancer.
Merck Pays Ariad to Take Control of Possible Cancer Treatment 2010
-
Ariad shares jumped higher on Tuesday after the company reported positive Phase III results for its ridaforolimus drug to target soft tissue or bone tumors.
Ariad And Merk Get Merry About Positive Phase III Data MarketNewsVideo.com 2011
-
Ariad shares jumped higher on Tuesday after the company reported positive Phase III results for its ridaforolimus drug to target soft tissue or bone tumors.
Ariad And Merk Get Merry About Positive Phase III Data MarketNewsVideo.com 2011
-
Under the agreement, Merck will pay a $50 million up-front fee and has acquired full control of the development and global commercialization of ridaforolimus.
Merck Pays Ariad to Take Control of Possible Cancer Treatment 2010
-
Ariad is also eligible to receive up to $514 million of milestone payments, and Merck will reimburse Ariad for its ridaforolimus-related expenses incurred since Jan 1, which total about $19 million.
Merck Pays Ariad to Take Control of Possible Cancer Treatment 2010
-
The drugs Merck plans to submit for regulatory approval this year are: boceprevir for hepatit is C; an extended-release version of diabetes drug Janumet; oral contraceptive Nomac/E2; a single-dose combination of the diabetes drug Januvia and cholesterol drug simvastatin; and cancer drug ridaforolimus.
-
Recently, Ariad Pharmaceuticals, in partnership with Merck, announced positive results from a Phase 3 study of their sarcoma drug, ridaforolimus.
unknown title 2011
-
Studies showed a 28 percent reduction in the risk of progression or death in those treated with ridaforolimus compared to placebo.
unknown title 2011
-
Merck and ARIAD previously announced that the European Medicines Agency had accepted the marketing authorization application for ridaforolimus.
unknown title 2011
-
ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications.
unknown title 2011
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.